Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vifor Pharma: Targets Acquisitions As Pure-Play Strategy Delivers

Executive Summary

Switzerland’s leader in iron deficiency therapies wants to add new products in this and adjacent therapeutic areas, as strong revenue growth in 2018 backs its strategy of concentrating its efforts on the pharmaceuticals business.

 

Advertisement

Related Content

ChemoCentryx/Vifor Change Tack On EU Avacopan Filing
AZ/FibroGen's Roxadustat Superior To Epoetin-Alfa In Chronic Renal Disease With Anemia
Potassium Lowering Therapies Hit NICE Hurdle In UK
Cara’s Partnership With Vifor Fresenius Provides Validation For Pruritis Drug Korsuva

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124907

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel